Biocelect is actively involved in the sourcing, in-licencing, and the commercialisation of pharmaceutical and in vitro diagnostic products for the Australian, New Zealand and Pacific region. We aim to contribute to meeting the medical needs of patients in the region. Biocelect is a growing business now having successfully had a range of products approved through the TGA (Therapeutic Goods Administration) and MedSafe New Zealand. These include two travel medicines, an intravenous influenza antiviral and a novel diagnostic. Biocelect has other products being evaluated that it hopes to be able to add to its growing portfolio over 2021 and 2022. Being an agile company, we can provide a range of bespoke partnering solutions for companies wanting to provide their products in the region for patients to access. Biocelect has an experienced and seasoned team with the ability to draw on the experience of its companion company, Biointelect, www.biointelect.com and Biointelect's cross functional expertise and experienced biopharmaceutical and MedTech industry staff. This allows Biocelect the ability to provide the functionality of a bigger company to partners and ensuring the success of their product. With the aim of meeting the medical needs of the patient.